Ginkgo Bioworks Holdings Inc vs iShares MSCI Singapore ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.92 (market cap $763.64M), while iShares MSCI Singapore ETF trades at $31.6 (market cap $1.49B). The key difference: iShares MSCI Singapore ETF is the larger of the two by market cap, and Ginkgo Bioworks Holdings Inc is more actively traded (3,204,177 versus 2,142,305). Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and iShares MSCI Singapore ETF for 45 Days on average.
| DNA | EWS | |
|---|---|---|
Market Cap | $763.64M | $1.49B |
Volume | 3,204,177 | 2,142,305 |
Sector | Health | Broad Market / Factor |
52-Week High | $15.83 | $34.57 |
52-Week Low | $5.48 | $26.71 |
Typical Hold Time | 7 Days | 45 Days |
Enterprise Value | $865.59M | — |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.
While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.
EWS, the iShares MSCI Singapore ETF, trades at $32.48, down 2.17% amid bearish technical signals. The ETF recently hit a 52-week high, driven by Singapore's economic strength and AI momentum, but faces selling pressure with key support at $32. Financial ratios are unavailable, limiting fundamental clarity.
Outlook remains mixed; Singapore's growth and institutional interest offer upside, but stretched valuations and technical weakness pose risks. Investors should weigh regional economic resilience against potential pullbacks in a volatile market.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →